Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Orogen Royalties Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2020-01-01

Employees: 10K

Market Cap: -

Website: http://www.organon.com

Introduction: Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

Phase 1

Completed

Conditions: Hypercholesterolemia
Atherosclerosis

Interventions: Drug: Ezetimibe + Rosuvastatin
Drug: Placebo
Drug: Ezetimibe
Drug: Rosuvastatin

First Posted Date: 2008-04-02

Last Posted Date: 2022-02-17

Lead Sponsor: Organon and Co

Target Recruit Count: 40

Registration Number: NCT00651144

An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)

Phase 1

Completed

Conditions: Infertility

Interventions: Drug: Org 36286
Drug: Lyndiol®

First Posted Date: 2008-04-01

Last Posted Date: 2022-02-03

Lead Sponsor: Organon and Co

Target Recruit Count: 24

Registration Number: NCT00647933

4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)

Phase 1

Completed

Conditions: Osteoporosis

Interventions: Drug: alendronate sodium (+) cholecalciferol

First Posted Date: 2008-03-24

Last Posted Date: 2022-02-02

Lead Sponsor: Organon and Co

Target Recruit Count: 56

Registration Number: NCT00641771

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Montelukast
Drug: Placebo

First Posted Date: 2008-03-14

Last Posted Date: 2024-05-09

Lead Sponsor: Organon and Co

Target Recruit Count: 46

Registration Number: NCT00636207

Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)

Phase 2

Completed

Conditions: Airway Inflammation
Asthma

Interventions: Drug: mometasone furoate/formoterol 200/10 mcg
Drug: mometasone furoate/formoterol 100/10 mcg
Drug: MF MDI 200 mcg
Drug: MF DPI 200 mcg
Drug: Placebo
Drug: mometasone furoate/formoterol 400/10 mcg

First Posted Date: 2008-03-14

Last Posted Date: 2024-05-14

Lead Sponsor: Organon and Co

Target Recruit Count: 93

Registration Number: NCT00635882

A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: Implanon (etonogestrel implant)
Drug: Radiopaque Implanon

First Posted Date: 2008-02-21

Last Posted Date: 2022-02-04

Lead Sponsor: Organon and Co

Target Recruit Count: 108

Registration Number: NCT00620464

A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: Radiopaque Etonogestrel Implant

First Posted Date: 2008-02-21

Last Posted Date: 2022-02-04

Lead Sponsor: Organon and Co

Target Recruit Count: 301

Registration Number: NCT00620035

Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)

Phase 1

Completed

Conditions: Migraine Disorders

Interventions: Drug: rizatriptan benzoate (5 mg)
Drug: Rizatriptan 5 mg Placebo
Drug: rizatriptan benzoate (10 mg)
Drug: Rizatriptan 10 mg Placebo

First Posted Date: 2008-01-30

Last Posted Date: 2024-04-19

Lead Sponsor: Organon and Co

Target Recruit Count: 31

Registration Number: NCT00604812

A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)

Phase 3

Completed

Conditions: COPD
Asthma

Interventions: Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )

First Posted Date: 2008-01-30

Last Posted Date: 2024-05-20

Lead Sponsor: Organon and Co

Target Recruit Count: 272

Registration Number: NCT00604500

An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma

Phase 3

Completed

Conditions: Allergic Rhinitis
Asthma

Interventions: Drug: Mometasone furoate nasal spray (MFNS)
Drug: Placebo nasal spray

First Posted Date: 2008-01-23

Last Posted Date: 2024-05-21

Lead Sponsor: Organon and Co

Target Recruit Count: 51

Registration Number: NCT00599027

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy